期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 16, 期 7, 页码 777-793出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2016.1181543
关键词
Multiple sclerosis; brain atrophy; gray matter; measurement; pseudoatrophy; biological confounding factors; disability; cognition; disease-modifying treatment; clinical routine
资金
- Teva Neuroscience
- Biogen Idec
- EMD Serono
- Questcor Pharmaceuticals
- Genzyme
- Bracco
- Claret Medical
- Novartis
- Czech Ministry of Education [PRVOUK-P26/LF1/4]
- Czech Science Foundation [GA CR 16-03322S]
- Merck
- Bayer
- Sanofi Genzyme
- Teva
- Teva Pharmaceuticals
- GenzymeSanofi
- Acorda
- Shire Pharmaceuticals
- Czech Ministry of Health [RVO-VFN64165/2012]
- Merck Serono
Introduction: Brain atrophy measurement in multiple sclerosis (MS) has become an important outcome for determining patients at risk for developing physical and cognitive disability. Areas covered: In this article, we discuss the methodological issues related to using this MRI metric routinely, in a clinical setting. Understanding trajectories of annualized whole brain, gray and white matter, thalamic volume loss, and enlargement of ventricular space in specific MS phenotypes is becoming increasingly important. Evidence is mounting that disease-modifying treatments exert a positive effect on slowing brain atrophy progression in MS. Expert Commentary: While there is a need to translate measurement of brain atrophy to clinical routine at the individual patient level, there are still a number of challenges to be met before this can actually happen, including how to account for biological confounding factors and pseudoatrophy, standardize acquisition and analyses parameters, which can influence the accuracy of the assessments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据